Breast Cancer Clinical Trial
Official title:
X-Ray Mammography Standard of Care Protocol
Verified date | September 20, 2011 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Background:
- X-ray mammography is the standard method for breast cancer screening. It is a
noninvasive test using x-rays to take pictures of breast tissue and detect any
abnormalities.
- The National Institutes of Health (NIH) Clinical Center has a breast imaging unit that
has been accredited by the American College of Radiology. To maintain accreditation, the
unit must recruit a certain number of women to have clinical mammograms each year in
order to maintain a high level of clinical skills and experience for the radiologists
and technologists.
Objectives:
- To create a state-of-the-art mammography unit at the NIH Clinical Center in order to
maintain American College of Radiology accreditation of the NIH breast imaging facility.
Eligibility:
- Women who are eligible for breast cancer screening because of family cancer history,
genetic test results, or previous instances of cancer. Participants may not be pregnant or
nursing at the time of the screening.
Design:
- Participants will provide a brief medical history on arrival at the NIH breast imaging
unit.
- Each participant will have a standard mammogram performed by a radiology technician.
- If the study is normal, participants will be told that no further evaluation will be
performed. If the results indicate a need for further imaging or tissue biopsy,
participants may elect to return to the care of their primary physician or to receive
further follow-up at the NIH Clinical Center.
Status | Completed |
Enrollment | 108 |
Est. completion date | September 20, 2011 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 100 Years |
Eligibility |
- INCLUSION CRITERIA: Women who are clinically indicated for screening mammography according to the National Comprehensive Cancer Network (NCCN) guidelines (3) and the American Cancer Society guidelines: 1. All women who fall under the ACS mammography guidelines 2. Women younger than 40 years but with more than 20% lifetime risk for developing breast cancer: 1. Prior personal history of prior thoracic radiation therapy between the age of 10 and 30, such as for Hodgkin's disease. In this case, women are eligible beginning 8-10 years after radiotherapy or at age 40, whichever comes first. 2. 5-year risk of invasive breast cancer (greater than or equal to 1.7% of women greater than or equal to 35 years or women who have a life time risk greater than 20% as defined by models that are largely dependent on family history. 3. Strong family history; i. First degree relative diagnosed with breast, ovarian, fallopian tube, or primary peritoneal cancer. ii. Individual from families known to have BRCA 1 or 2 gene mutation. iii. Close male blood relative with breast cancer. d. Genetic predisposition; i. Carry or have first-degree relative who carries a genetic mutation in the BRCA 1 or 2 genes. ii. Carry or have a first-degree relative who carries a genetic mutation in the TP53 or PTEN genes (Li-Fraumeni syndrome and Cowden Bannayan-Riley-Ruvalcaba syndromes). e. A personal history of Lobular carcinoma in situ (LCIS) and/or atypical ductal hyperplasia (ADH) f. Prior personal history of breast cancer or ovarian cancer. i. Starting at the age of 25 year for Hereditary breast and ovarian cancer patients. ii. 5-10 years prior to youngest breast cancer case for strong family history or other genetic predisposition. g. Woman and Minorities EXCLUSION CRITERIA: Pregnant or lactating subjects. |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institutes of Health Clinical Center (CC) |
United States,
Belkacémi Y, Bousquet G, Marsiglia H, Ray-Coquard I, Magné N, Malard Y, Lacroix M, Gutierrez C, Senkus E, Christie D, Drumea K, Lagneau E, Kadish SP, Scandolaro L, Azria D, Ozsahin M. Phyllodes tumor of the breast. Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):492-500. Epub 2007 Oct 10. — View Citation
Destouet JM, Bassett LW, Yaffe MJ, Butler PF, Wilcox PA. The ACR's Mammography Accreditation Program: ten years of experience since MQSA. J Am Coll Radiol. 2005 Jul;2(7):585-94. — View Citation
Geller BM, Ichikawa LE, Buist DS, Sickles EA, Carney PA, Yankaskas BC, Dignan M, Kerlikowske K, Yabroff KR, Barlow W, Rosenberg RD; Breast Cancer Surveillance Consortium. Improving the concordance of mammography assessment and management recommendations. Radiology. 2006 Oct;241(1):67-75. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |